



## Ongoing Disclosure Notice

### Disclosure of Directors and Senior Managers Relevant Interests

Sections 297(2) and 298(2), Financial Markets Conduct Act 2013

|                            |                            |
|----------------------------|----------------------------|
| To NZX Limited; and ASX    |                            |
| Name of listed issuer:     | Oceania Healthcare Limited |
| Date this disclosure made: | 29 September 2023          |
| Date of last disclosure:   | 29 June 2023               |

#### Director or senior manager giving disclosure

|   |                            |
|---|----------------------------|
| Full name(s):                                   | Brent Pattison             |
| Name of listed issuer:                          | Oceania Healthcare Limited |
| Name of related body corporate (if applicable): | N/A                        |
| Position held in listed issuer:                 | Chief Executive Officer    |

#### Summary of acquisition or disposal of relevant interest (excluding derivatives)

|  |  |
|--|--|
| Class of affected quoted financial products:         | Ordinary shares  |
| Nature of the affected relevant interest(s):         | Registered and/or beneficial ownership of ordinary shares  |
| <b>For that relevant interest -</b>                  |  |
| Number held in class before acquisition or disposal: | (1) Beneficial interest in 2,231 ordinary shares issued under the Oceania Healthcare Employee Share Scheme<br>(2) Registered and beneficial ownership of 365,912 ordinary shares |
| Number held in class after acquisition or disposal:  | (1) Beneficial interest in 2,525 ordinary shares issued under the Oceania Healthcare Employee Share Scheme<br>(2) Registered and beneficial ownership of 366,678 ordinary shares |
| Current registered holder(s):                        | (1) OCA Employees Trustee Limited<br>(2) Brent Pattison  |
| Registered holder(s) once transfers are registered:  | As above   |

#### Summary of acquisition or disposal of specified derivatives relevant interest (if applicable)

|   |     |
|---|-----|
| Type of affected derivative:            | N/A |
| Class of underlying financial products: | N/A |

**Details of affected derivative -**

|   |     |
|---|-----|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):   | N/A |
| A statement as to whether the derivative is cash settled or physically settled:   | N/A |
| Maturity date of the derivative (if any):   | N/A |
| Expiry date of the derivative (if any):   | N/A |
| The price specified in the terms of the derivative (if any):  | N/A |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | N/A |

*For that derivative: -*

|  |     |
|--|-----|
| Parties to the derivative:   | N/A |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | N/A |

**Details of transactions giving rise to acquisition or disposal**

|   |   |
|---|---|
| Total number of transactions to which notice relates: | 2 |
|---|---|

**Details of transactions requiring disclosure -**

|  |  |
|--|--|
| Date of transaction:   | (1) 25 September 2023<br>(2) 29 September 2023   |
| Nature of transaction:   | (1) Acquisition of beneficial interest in 1060 ordinary shares in Oceania Healthcare Limited in accordance with the Employee Share Scheme<br><br>(2) Vesting of 766 ordinary shares pursuant to the terms of the Oceania Healthcare Employee Share Scheme and transfer of those vested ordinary shares from OCA Employees Trustee Limited to personal name |
| Name of any other party or parties to the transaction (if known):  | OCA Employees Trustee Limited  |
| The consideration, expressed in New Zealand dollars, paid or received for the acquisition or disposal. If the consideration was not in cash and cannot be readily converted into a cash value, describe the consideration: | (1) Nil<br>(2) N/A – vesting and transfer of vested shares   |
| Number of financial products to which the transaction related:   | (1) 1060<br>(2) 766  |

*If the issuer has a financial products trading policy that prohibits directors or senior managers from trading during*

---

any period without written clearance (a closed period)  
include the following details -

|  |     |
|--|-----|
| Whether relevant interests were acquired or disposed of during a closed period:  | No  |
| Whether prior written clearance was provided to allow the acquisition or disposal to proceed during the closed period: | N/A |
| Date of the prior written clearance (if any):  | N/A |

**Summary of other relevant interests after acquisition or disposal:**

|                                     |     |
|-------------------------------------|-----|
| Class of quoted financial products: | N/A |
| Nature of relevant interest:        | N/A |

*For that relevant interest -*

|                               |     |
|-------------------------------|-----|
| Number held in class:         | N/A |
| Current registered holder(s): | N/A |

*For a derivative relevant interest -*

|                     |     |
|---------------------|-----|
| Type of derivative: | N/A |
|---------------------|-----|

**Details of derivative -**

|   |     |
|---|-----|
| The notional value of the derivative (if any) or the notional amount of underlying financial products (if any):   | N/A |
| A statement as to whether the derivative is cash settled or physically settled:   | N/A |
| Maturity date of the derivative (if any):   | N/A |
| Expiry date of the derivative (if any):   | N/A |
| The price's specified terms (if any):   | N/A |
| Any other details needed to understand how the amount of the consideration payable under the derivative or the value of the derivative is affected by the value of the underlying financial products: | N/A |

*For that derivative relevant interest:*

|  |     |
|--|-----|
| Parties to the derivative:   | N/A |
| If the director or senior manager is not a party to the derivative, the nature of the relevant interest in the derivative: | N/A |

**Certification**

|   |  |
|---|--|
| I certify that, to the best of my knowledge and belief, the information contained in this disclosure is correct and that I am duly authorised to make this disclosure by all persons for whom it is made. |  |
| Signature of director or officer:   |  |
| Date of signature:  |  |

or

---

Signature of person authorised to sign on behalf of director or officer:



Date of signature:

29 September 2023

Name and title of authorised person:

Anna Thorburn  
Group General Manager  
Corporate Services